{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:40:47Z","timestamp":1793252447202,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n            <jats:title>Background and aims<\/jats:title>\n            <jats:p>Italian guideline suggests 10-day sequential or bismuth-based quadruple therapies for first-line <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic> treatment. Comparison between these regimens is lacking. We assessed the efficacy of these therapies in clinical practice and evaluated the role of primary bacterial resistance toward clarithromycin and metronidazole.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Consecutive patients with <jats:italic toggle=\"yes\">H. pylori<\/jats:italic> infection were enrolled. Bacterial culture with antibiotics susceptibility testing was attempted in all cases. Patients received either a sequential therapy with esomeprazole 40\u2009mg for 10 days plus amoxicillin 1000\u2009mg for the first 5 days followed by clarithromycin 500\u2009mg and tinidazole 500\u2009mg (all twice daily) for the remaining 5 days, or bismuth-based therapy with esomeprazole 20\u2009mg twice daily and Pylera 3 tablets four times daily for 10 days. <jats:italic toggle=\"yes\">H. pylori<\/jats:italic> eradication was assessed by using <jats:sup>13<\/jats:sup>C-urea breath test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 495 patients were enrolled. Following sequential (250 patients) and quadruple (245 patients) therapies, the eradication rate were 92 and 91%, respectively, at intention-to-treat analysis and 96 and 97%, respectively, at per protocol analysis. Overall, the pattern of bacterial resistance did not significantly affect the cure rate, but the presence of clarithromycin and metronidazole dual resistance tended to reduce the success rate of both sequential (84.8 vs. 90.1%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.4) and quadruple (85 vs. 94.1%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.06) therapies. Adverse events occurred more frequently with the quadruple than with sequential therapy (56.9 vs. 25.8%; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In our country, sequential and bismuth-based quadruple therapy achieved similarly high eradication rates as first-line treatments for <jats:italic toggle=\"yes\">H. pylori<\/jats:italic> infection in clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000001102","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T18:04:09Z","timestamp":1519409049000},"page":"621-625","source":"Crossref","is-referenced-by-count":35,"title":["Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice"],"prefix":"10.1097","volume":"30","author":[{"given":"Giulia","family":"Fiorini","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, S. Orsola Hospital, University of Bologna, Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Zullo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, \u2018Nuovo Regina Margherita\u2019 Hospital, Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria M.","family":"Saracino","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, S. Orsola Hospital, University of Bologna, Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gatta","sequence":"additional","affiliation":[{"name":"Gastroenterogy and Endoscopy Unit, Versilia Hospital, Lido di Camaiore, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pavoni","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, S. Orsola Hospital, University of Bologna, Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Vaira","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, S. Orsola Hospital, University of Bologna, Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.dld.2015.06.010","article-title":"Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015","volume":"47","author":"Zagari","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"R6-20230916","first-page":"409","article-title":"Worldwide H. pylori antibiotic resistance: a systematic review","volume":"19","author":"De Francesco","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20230916","first-page":"231","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use","volume":"48","year":"1997","journal-title":"Int Dig Health Legis"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11739-009-0344-2","article-title":"A comparison among three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic","volume":"1","author":"Vaira","year":"2010","journal-title":"Intern Emerg Med"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cgh.2012.12.007","article-title":"Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection","volume":"11","author":"Fiorini","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1756283X09343326","article-title":"Sequential therapy for Helicobacter pylori eradication: the time is now","volume":"2","author":"Vaira","year":"2009","journal-title":"Ther Adv Gastroenterol"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"f4587","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy","volume":"347","author":"Gatta","year":"2013","journal-title":"BMJ"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases \u2013 a position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"147","DOI":"10.15403\/jgld.2014.1121.252.2w3","article-title":"Two-week triple therapy with either standard or high-dose esomeprazole for first-line H. pylori eradication","volume":"25","author":"De Francesco","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/gast.1996.v111.agast961110521","article-title":"Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy","volume":"111","author":"Lambert","year":"1996","journal-title":"Gastroenterology"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1523-5378.2001.00022.x","article-title":"Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?","volume":"6","author":"Phillips","year":"2001","journal-title":"Helicobacter"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/ajg.2017.386","article-title":"Is double-dose esomeprazole with bismuth really safe?","volume":"112","author":"Zullo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MCG.0b013e318247177e","article-title":"Predicting Helicobacter pylori eradication. How to teach an old dog new trick","volume":"46","author":"Zullo","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11739-010-0443-0","article-title":"Helicobacter pylori eradication: are we really equal? A controlled study in native and immigrant population","volume":"6","author":"Gatta","year":"2011","journal-title":"Intern Emerg Med"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11739-010-0477-3","article-title":"Helicobacter pylori in immigrants: a \u2018foreign\u2019 bacterium?","volume":"6","author":"Zullo","year":"2011","journal-title":"Intern Emerg Med"},{"key":"R23-20230916","first-page":"373","article-title":"First-line therapies for Helicobacter pylori eradication: a critical reappreasil of updated guidelines","volume":"30","author":"De Francesco","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gut.2007.125658","article-title":"The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis","volume":"56","author":"Zullo","year":"2007","journal-title":"Gut"},{"key":"R25-20230916","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12423","article-title":"Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera\u00ae) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study","author":"Rodr\u00edguez de Santiago","year":"2017","journal-title":"Helicobacter"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clinre.2015.12.012","article-title":"Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains","volume":"40","author":"Muller","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R27-20230916","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12371","article-title":"New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: a first Italian experience in clinical practice","author":"Tursi","year":"2017","journal-title":"Helicobacter"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042737-201806000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:05:10Z","timestamp":1694876710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201806000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000001102","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}